Contents

Search

tbo filgrastim

See filgrastim Indications: - attenuation of chemotherapy-induced neutropenia Dosage: - administered as an injection beginning 24 hours after chemotherapy treatment Adverse effects: - bone pain Mechanism of action: - stimulates bone marrow production of neutrophils Notes: - FDA has not approved tbo-filgrastim as a biosimilar to Neupogen (filgrastim)

General

filgrastim [G-CSF] (Neupogen, Lenograstim, Granulokine)

References

  1. FDA News Release: Aug. 29, 2012 FDA approves new treatment for severe neutropenia in certain cancer patients http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317392.htm